



INTERNATIONAL QUALITY  
PLASMA PROGRAM

# **IQPP Corporate Audit Report Form and Checklist**

**Version 10.1**

**Implemented April 1, 2021**



## IQPP Corporate Audit Report Form Version 10.1

PPTA ID# \_\_\_\_\_

Auditor \_\_\_\_\_

Company \_\_\_\_\_

Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip code \_\_\_\_\_

Government Authority Identification \_\_\_\_\_

Telephone \_\_\_\_\_

Manager \_\_\_\_\_

Medically Qualified Person \_\_\_\_\_

Person Responsible for Q/A \_\_\_\_\_

Recipient's email address \_\_\_\_\_

Date of audit \_\_\_\_\_ Start Time \_\_\_\_\_

End Time \_\_\_\_\_

Auditor Recommendation:

For Certification/Recertification

For Certification/Recertification, pending resolution of issues listed on report form,

Section(s) \_\_\_\_\_

Recommendations for specific sections \_\_\_\_\_

Recommend Re-audit within \_\_\_\_\_ days.

**PPTA Review** \_\_\_\_\_ **Date Reviewed** \_\_\_\_\_



**Auditor's Statement**

As an Auditor for the International Quality Plasma Program (IQPP), I shall not, either directly or indirectly, for myself or for the benefit of or in conjunction with any other person, corporation, partnership, association, agency, department, or other legal entity, use, communicate or otherwise disclose, or permit to be disclosed, any Confidential Information relating to this audit or company without prior written consent of such company; provided, however, Auditor may, only to the extent reasonably necessary or appropriate to the performance of Auditor's duties, disclose such Confidential Information to PPTA or an employee of PPTA for use in the IQPP Certification or a person to whom disclosure is otherwise required by applicable state or federal law or regulation.

All information obtained during audit will be forwarded to PPTA to be made a part of the company's IQPP certification file.

As a consultant appointed by PPTA to perform this company's IQPP audit, I hereby attest that to the best of my knowledge no conflict of interest exists between my current clients and the audited company and/or PPTA.

As a consultant for the purposes of performing the IQPP audit of said company, I certify that the attached audit findings and comments are true and accurate findings based on my observations and record review during the audit.

Auditor Signature \_\_\_\_\_ Date \_\_\_\_\_

**POST AUDIT REVIEW**

I acknowledge that the Auditor has reviewed the observations listed in this report. My signature does not constitute concurrence or denial of any of the observations made by the Auditor.

Company Representative \_\_\_\_\_ Date \_\_\_\_\_

Title \_\_\_\_\_ Center Name/Location \_\_\_\_\_



## IQPP Corporate Audit Checklist Version 10.1

<b>A – Qualified Donors, Donor Record File (DRF) Review &amp; Donor Privacy</b>				
#	Audit Question	Yes	No	Ranking
1.	Does the company have written procedures in place, or, in the case of automated donor process, functional documentation (specifications/validation) in place that conforms to the IQPP Qualified Donor Standard?			Critical
2.	Does the company have written procedures to track Applicant Donor Units (orphan units) as to their final disposition?			Critical
<u>Auditor Comments on Section A:</u>    				
<b>B – Community-Based Donor Population</b>				
#	Audit Question	Yes	No	Ranking
1.	Does the company have written procedures in place that conform to the IQPP Community-Based Donor Standard?			Critical
<u>Auditor Comments on Section B:</u>    				
<b>C – Use of the National Donor Deferral Registry or centralized donor deferral registry usage</b>				
#	Audit Question	Yes	No	Ranking
1.	Does the company have written procedures in place that conform to the IQPP Use of the NDDR Standard?			Critical
<u>Auditor Comments on Section C:</u>    				



<b>D – Donor Education</b>				
<b>#</b>	<b>Audit Question</b>	<b>Yes</b>	<b>No</b>	<b>Ranking</b>
1.	Does the company have written procedures in place that conform to the IQPP Donor Education Standard?			Major
2.	Can the company show evidence of donor education material that is provided to the plasma centers to educate donors?			Minor
<u>Auditor Comments on Section D:</u>				
<b>E – Personnel Education and Training</b>				
<b>#</b>	<b>Audit Question</b>	<b>Yes</b>	<b>No</b>	<b>Ranking</b>
1.	Does the company have a training program with instructions or procedures to be performed by the trainee for each relevant plasma center job function?			Major
2.	Does the training program require employees to perform tasks under direct supervision of designated trainers, who are physically present in the area until their competency in the tasks is established and documented in accordance with the program’s competency requirements?			Minor
3.	Does the company have a written procedure in place which requires annual current Good Manufacturing Practices (cGMP) and Exposure Control Plan (biosafety practices and procedures) training for all plasma center employees, when the training is applicable for an employee’s specified job description?			Major
4.	Is there a policy and process in place to verify that plasma center employees (with a functional job related to donor screening, plasma collection, product handling or other similar functions) have attained the minimum level of education required in the Standard?			Minor
<u>Auditor Comments on Section E:</u>				



**F – Plasma Collection Facility**

NOTE: There are no questions from this section that are applicable for the Corporate Audit.

**G – Complaints**

#	Audit Question	Yes	No	Ranking
1.	Does the company have written procedures available for receiving, recording and evaluating customer and/or donor complaints?			Major

Auditor Comments on Section G:

**H – Quality Assurance Standard**

#	Audit Question	Yes	No	Ranking
1.	Does the company have written procedures in place that conform to the IQPP Quality Assurance Standard?			Critical
2.	Does Quality Assurance/responsible person have the authority and responsibility as outlined by the plasma center SOP or job description to stop a) the release of plasma for shipment, if necessary? b) plasma center production, if necessary?			Critical
3.	Does the company have written procedures that outline and instruct Quality Assurance/responsible person on the specific checks that must be verified as acceptable before plasma units are released?			Critical
4.	Is final plasma release controlled by Quality Assurance personnel or a qualified alternate?			Critical

Auditor Comments on Section H:



<b>I – Viral Marker Standard</b>				
<b>#</b>	<b>Audit Question</b>	<b>Yes</b>	<b>No</b>	<b>Ranking</b>
1.	Does the company have written procedures in place that conform to the IQPP Viral Marker Standard?			Critical
2.	If the data are computer-generated, is the query set up to classify Applicant and Qualified Donors according to the IQPP Qualified Donor Standard?			Major
<u>Auditor Comments on Section I:</u>				
<b>J – Cross Donation Management Standard</b>				
<b>#</b>	<b>Audit Question</b>	<b>Yes</b>	<b>No</b>	<b>Ranking</b>
1.	Does the company have written procedures that conform to the IQPP Cross Donation Management Standard?			Major
2.	Do the written procedures include how it will prevent an individual from donating more often than allowed by regulation?			Major
3.	Do the written procedures include a notification process to inform all known plasma centers within a center’s Donor Recruitment Area (“DRA”) of the opening of a new center and provide all required information to the Cross Donation Check System (“CDCS”) no later than 30 days prior to the scheduled opening date?			Major
4.	Do the written procedures include an articulated backup process in accordance with subclause 4.4 of the standard?			Major
5.	Do the written procedures include a process for transfer of required donor donation information to the CDCS?			Major
6.	Do the written procedures include a process to investigate situations when the data transfer fails?			Major
7.	Do the written procedures include an articulated process to determine whether an individual, found to be listed in the CDCS, is knowingly attempting to violate the donation frequency allowed by regulation?			Major
8.	Do the written procedures include an articulated process to apply a permanent deferral to a donor who is found i. to be knowingly attempting to donate more often than regulation allows, or			Major



	ii. to have cross-donated?			
9.	Do the written procedures include an SOP requiring use of the CDCS (or, where the CDCS is not permissible by law, an alternative national or regional registry, if available, and, where no alternate deferral registry is available, an intra-company process) in accordance with the Standard?			Major

Auditor Comments on Section J:

**K – Standard for Recording Donor Adverse Events**

#	Audit Question	Yes	No	Ranking
1.	Does the company have a documented process for recording known Donor Adverse Events (“DAEs”) considered to be associated with any part of a Source Plasma donation program (this includes initial screening, donation, immunization for high titer collections, etc.) following company approved SOPs, and does this process conform to the Standard?			Major
2.	Does the process require centers to record, in the facility’s documentation system, DAEs as required by the Standard?			Major

Auditor Comments on Section K:

**L – Donor Fluid Administration Standard**

#	Audit Question	Yes	No	Ranking
1.	Does the company have written procedures that address the requirements in the standard?			Critical

Auditor Comments on Section L:





General Overall Comments:

**Scoring Guidelines** (These guidelines are recommendations only and are not meant to be the sole factor in making a determination regarding certification or re-audit timeframe.):

Critical Observations       = 50 points each  
Major Observations         = 10 points each  
Minor Observations         = 2 points each

51 points or more triggers a procedure in which a re-audit in less than one (1) year may occur.